 ALPHARETTA, Ga., Aug. 25, 2022 GLOBE NEWSWIRE -- Clearside Biomedical, Inc. NASDAQ:CLSD, a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space SCS, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022. 